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In patients with acute liver failure (ALF), elevated prothrombin time and thrombocytopenia can fuel a perception of a
bleeding tendency. However, the incidence, site, risk factors, and clinical signiﬁcance of bleeding complications have
not been quantiﬁed in a large cohort of patients with ALF. We studied 1,770 adult patients enrolled in the ALF
Study Group Registry between 1998 and 2016. Bleeding complications and blood component transfusions were col-
lected for 7 days after admission. The relationship of bleeding complications to 21-day mortality was assessed. Despite
a median international normalized ratio of 2.7 and platelet count of 963 109/L on admission, bleeding complications
were observed in only 187 patients (11%), including 173 spontaneous and 22 postprocedural bleeding episodes.
Eighty-four percent of spontaneous bleeding episodes were from an upper gastrointestinal source and rarely resulted in
red blood cell transfusion. Twenty patients experienced an intracranial bleed; half of these occurred spontaneously and
half after intracranial pressure monitor placement, and this was the proximate cause of death in 20% and 50%, respec-
tively. Bleeders and patients who received red blood cell transfusions were more acutely ill from extrahepatic organ sys-
tem failure but not from hepatocellular failure. Consistent with this observation, bleeding complications were
associated with lower platelet counts but not higher international normalized ratio. Transfusion of any blood compo-
nent was associated with nearly 2-fold increased death or need for liver transplantation at day 21, but bleeding compli-
cations were the proximate cause of death in only 5% of cases. Conclusions. Despite a perceived bleeding diathesis,
clinically signiﬁcant bleeding is uncommon in patients with ALF; bleeding complications in patients with ALF are
markers of severe systemic inﬂammation rather than of coagulopathy and so portend a poor prognosis. (HEPATOLOGY
2018;67:1931-1942)
Abnormal hemostasis is integral to thedeﬁnition of acute liver failure (ALF) and ischaracterized by an elevated international
normalized ratio (INR) of the prothrombin time.(1)
Recent studies have suggested that, despite the fre-
quently intimidating elevation of the INR and moder-
ate thrombocytopenia, global hemostasis in most
patients with ALF remains normal or “rebalanced,” at
least in vitro.(2,3) Compensatory mechanisms have
been identiﬁed for each phase of hemostasis in
patients with ALF such that prohemostatic drivers
may actually overcompensate for deﬁcient liver-
derived coagulation factors and result in a relative
hypercoagulable state.(4)
Whether in vitro rebalance equates with clinical
rebalance and a low risk of bleeding complications in
patients with ALF has not been determined. Early
clinical series suggested that patients with ALF had a
propensity to bleed and that bleeding episodes resulted
in increased morbidity and mortality.(5-7) Capillary-
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type bleeding from mucosal erosions of the upper gas-
trointestinal (UGI) tract were most frequently iden-
tiﬁed as the source of bleeding, but other mucosal
sites included the nasopharynx, lung, and female geni-
tourinary tract.(7) Curiously, there has been scant
mention of the bleeding incidence or its contribution
to the morbidity and mortality of patients with ALF
in recent series, leading to a perception that bleeding
complications are not an important determinant of
outcome. For example, in one of the largest series of
ALF patients ever reported (over 2,000 cases), bleed-
ing was not mentioned as a complication of ALF or a
cofactor in poor outcome.(8) The absence of a con-
temporary update on the incidence and signiﬁcance of
bleeding complications and the recent laboratory evi-
dence of rebalanced hemostasis may have contributed
to the recommendation that “no routine correction of
coagulation abnormalities” is warranted in patients
with ALF.(9)
Routine assays of hemostasis performed in vitro may
not reﬂect hemostasis in vivo accurately; all coagula-
tion assays are deﬁcient in certain components of the
hemostatic system, for example, endothelial factors,(10)
anticoagulant pathways, and activated platelets. Never-
theless, clinicians continue to rely on the INR to assess
bleeding risk, either from spontaneous bleeding or
after an invasive procedure. In the present study, we
have sought to reanalyze the risk of bleeding in
patients with ALF enrolled in the US ALF Study
Group Registry. The registry has prospectively col-
lected clinical and laboratory data on more than 2,800
patients with ALF since 1998, including bleeding
complications and transfusions of blood components
early after admission. In the present work, we quanti-
ﬁed the incidence of spontaneous and postprocedural
bleeding complications; estimated the severity of
bleeding; and explored the indications for blood com-
ponent transfusion, associated bleeding complications,
and receipt of transfusions to 21-day outcome of
patients with ALF.
Patients and Methods
PATIENTS
Study patients were recently described,(11) and
accrual in the present study followed the algorithm in
Supporting Fig. S1. ALF was deﬁned by standard cri-
teria reported by the ALF Study Group.(12) All
patients with ALF in the ALF Study Group Registry
enrolled between January 1, 1998, and January 1,
2016, were eligible for inclusion. Of the 2,345 patients
who were screened, 575 (24%) were excluded for miss-
ing data. The 21-day outcome of the remaining 1,770
patients who met entry criteria included 781 (44%)
who recovered without liver transplantation (LT;
spontaneous survivors), 430 (24%) who underwent
LT, and 559 (32%) who died.
As the percent of excluded patients due to missing
data was signiﬁcant, we performed a comparison of
included and excluded registry enrollees (Supporting
Table S1). Excluded patients appear to have been less
acutely ill than included patients, and the missing data
suggest that they were less intensively followed. Speciﬁ-
cally, excluded patients were less likely to have the sys-
temic inﬂammatory response syndrome (SIRS), were
less likely to have high-grade hepatic encephalopathy,
and had higher platelet counts and lower INRs on
admission than included patients. Excluded patients
were also slightly less likely to have had a bleeding com-
plication after study admission (7.4% versus 10.6%), less
likely to receive a blood component transfusion during
admission, and less likely to have died at 21 days than
included patients. However, bleeding complications as
the cause of death were similar in the two groups.
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DEFINITIONS AND DATA
COLLECTION
Bleeding complications were reported daily by the
study site clinical investigators from admission (day 1)
through day 7. No formal deﬁnition of bleeding was
speciﬁed in the registry’s manual of operations,
although sites were required to specify on each day
whether bleeding had occurred and, if so, the site of
origin. Bleeding was recorded as “gastrointestinal” or
“other,” where the other site of bleeding was required
to be entered manually. The case report forms for all
bleeders were reviewed by the study’s principal inves-
tigator (R.T.S.), classiﬁed as either spontaneous
(non-procedure-related) or postprocedural, and fur-
ther classiﬁed according to the site of bleeding. The
adjudication process was deliberately designed to be
overly inclusive without regard to the severity of
bleeding or whether the bleeding episode resulted in
red blood cell (RBC) transfusion. Additional bleeders
were identiﬁed through review of case report forms
where subjects were identiﬁed as having a hemorrhage
on imaging studies, as an intracranial pressure (ICP)
complication, or as the cause of death. Case report
forms of all patients in whom the site’s clinical inves-
tigator indicated that a bleeding complication con-
tributed to a patient’s death by day 21 were reviewed
in order to adjudicate the role of bleeding in the death
and to classify the bleeding as spontaneous or post-
procedural. Daily recording of the following was also
required: transfusion of blood products (RBCs, plate-
lets, and plasma); administration of vitamin K,
recombinant activated factor VII (rFVIIa), gastric
acid suppression, vasopressors, and N-acetylcysteine;
and management decisions including hemodialysis,
renal replacement therapy (RRT), mechanical ventila-
tion, liver biopsy, and ICP monitoring. Subjects were
not considered bleeders if the episode occurred during
or after LT.
STATISTICAL ANALYSIS
SAS software (version 9.4; Cary, NC) was used to
perform statistical analyses. Baseline variables were
described using counts and percentages for categorical
data or means and standard deviations (medians and
interquartile ranges) for continuous normal (skewed)
data. For variables identiﬁed as clinically relevant, sta-
tistical tests were performed using chi-squared, analysis
of variance, or Kruskal-Wallis tests. Modeling of
hemoglobin, platelet, and INR values over time was
performed using a linear mixed model with unstruc-
tured covariance for each patient to account for the
within-patient correlation across measurement days,
where bleeding was deﬁned as a dichotomous indicator
of bleeding at any time between admission and day 7,
LT, discharge, or death. The ﬁgures illustrate mean
hemoglobin, platelet, and INR estimates for each
observation day adjusted for the correlation across
measurement days (i.e., least square means). Hazards
of LT or death are shown as Kaplan-Meier curves with
log-rank test statistics. All statistical tests are reported
as two-sided with a type I error rate of 5%.
Results
INCIDENCE AND CLINICAL
CHARACTERISTICS OF
BLEEDING COMPLICATIONS
A total of 1,770 adults with ALF entered the study,
of whom 430 (24%) underwent LT and 559 (32%)
died by day 21. Two hundred thirty-seven patients
(13%) underwent ICP monitor placement, the proce-
dure with the highest potential morbidity and mortal-
ity from bleeding complications. One hundred ninety-
ﬁve bleeding complications occurred in 187 patients
with ALF (Table 1), for an overall incidence of 10.6%
TABLE 1. Sites and Causes of Bleeding Complications in Patients With ALF
Cause of Bleeding Bleeding Site
Total Occurrences*
(n)
Cause of Death
(n)
Spontaneous UGI 163 3
Intracranial 10 2
Postprocedural Venous access site 8 0
Intracranial (ICP monitor) 10 5
Nasopharyngeal 2 0
Genitourinary 2 0
Total 195 10
*n5 2 had both spontaneous UGI and spontaneous intracranial bleeding; n5 2 had both spontaneous UGI and postprocedural intra-
cranial bleeding; n5 4 had both spontaneous UGI and postprocedural bleeding at venous access site.
HEPATOLOGY, Vol. 67, No. 5, 2018 STRAVITZ ET AL.
1933
during the ﬁrst 7 days of admission; 8 patients experi-
enced more than one bleeding complication. Of all
bleeding episodes, 173 were spontaneous (89%) and 22
were postprocedural (11%). The vast majority of spon-
taneous bleeding complications were from a UGI
source (163 of 173 complications; 94%), with 10 addi-
tional spontaneous bleeds occurring at an intracranial
site either before placement or in the absence of an
ICP monitor. Postprocedural bleeding from venous
access sites was recorded in 8 cases, a nasopharyngeal
source after nasogastric tube placement in 2 cases, a
genitourinary source after urinary bladder catheteriza-
tion in 2 cases, and after ICP monitor placement in 10
cases, 5 of which resulted in death. In patients with a
TABLE 2. Demographic and Clinical Features of Patients With ALF With and Without Bleeding
Complications During Days 1-7
Clinical Feature n
Nonbleeders
(n5 1,583)
n6 SD (%)
Bleeders
(n5187)
n6 SD (%) P
Demographics
Age (years) 1,770 41615 426 14 0.499
Gender (% female) 1,770 1,109 (70.1) 112 (59.9) 0.006
Race (% Caucasian) 1,770 1,164 (73.5) 145 (77.5) 0.274
APAP etiology of ALF 1,770 710 (44.9) 88 (47.1) 0.62
Clinical features on admission
Symptoms to enrollment (days) 1,719 66 13 56 11 0.100
Plasma before admission 1,720 644 (41.9) 118 (64.8) <0.001
Anticoagulants 1,770 41 (2.6) 5 (2.7) —
Aspirin 1,770 83 (5.2) 17 (9.1) 0.047
SIRS (%2 components) 1,364 894 (74.4) 130 (80.2) 0.127
SIRS-temperature (n <36C or >38C) 1,710 425 (28) 66 (37) 0.014
SIRS-pulse (beats/minute) 1,757 97629 105632 <0.001
SIRS-respiratory rate (breaths/minute) 1,721 196 8 206 10 0.09
SIRS-PCO2 (mm Hg) 1,335 31610 306 10 0.028
SIRS-WBC (N <4 or >123109/L) 1,770 723 (46) 100 (53) 0.052
Ammonia (mM) 1,032 99.0695.0 93.06 79.5 0.244
Encephalopathy grade 3/4 1,721 733 (47.8) 115 (61.5) <0.001
Creatinine (mg/dL) 1,766 1.662.1 2.26 2.3 <0.001
INR 1,770 2.862.2 2.76 2.4 0.895
Total bilirubin (mg/dL) 1,752 7.66 16.4 6.86 13.1 0.226
Albumin (g/dL) 1,616 2.760.8 2.76 0.6 0.549
Lactate (mg/dL) 971 4.466.0 5.46 8.2 0.002
Bicarbonate (mg/dL) 1,481 22.06 8.0 20.06 10.0 0.002
Phosphate (mg/dL) 1,539 3.162.3 3.86 2.9 <0.001
Platelet count (3109/L) 1,770 1286108 966 92 <0.001
WBC (3109/L) 1,770 10.16 8.1 10.669.7 0.239
Hemoglobin (g/dL) 1,764 11.16 3.1 10.362.8 <0.001
Clinical features after admission, days 1-7
INR peak 1,770 3.362.7 3.26 3.3 0.22
Platelet count nadir (3109/L) 1,770 77681 536 45 <0.001
Hemoglobin nadir (g/dL) 1,770 9.262.5 8.46 2.1 <0.001
Encephalopathy grade 3/4 1,734 981 (63.4) 161 (86.1) <0.001
Infection 1,770 155 (9.8) 16 (8.6) 0.682
Interventions after admission, days 1-7
ICP monitor placement 1,634 201 (13.8) 36 (20.7) 0.019
RRT 1,770 534 (33.7) 107 (57.2) <0.001
Vasopressors 1,770 531 (33.5) 121 (64.7) <0.001
N-Acetylcysteine 1,770 967 (61.1) 121 (64.7) 0.378
Gastric acid suppression 1,770 1,267 (80.0) 162 (86.6) 0.039
RBC transfusion 1,770 265 (16.7) 30 (16.0) 0.89
Plasma transfusion 1,770 531 (33.5) 120 (64.2) <0.001
Platelet transfusion 1,770 849 (53.6) 145 (77.5) <0.001
Outcomes at day 21
TFS 1,770 723 (45.7) 58 (31.0) <0.001
LT 1,757 407 (25.9) 23 (12.4) <0.001
Died after LT 430 39 (9.6) 1 (4.3) <0.001
Died 1,770 492 (31.1) 107 (57.2) <0.001
Abbreviations: PCO2, partial pressure of carbon dioxide; WBC, white blood cell.
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recorded primary cause of death (484/599), bleeding
complications (spontaneous or postprocedural) were
deemed the proximate cause of death in 10 patients
(2.1%), 7 of whom had spontaneous or post-ICP mon-
itor intracranial bleeding. An additional 6 patients who
died between 8 and 21 days also had bleeding listed as
a cause of death (3.3%). Bleeding episodes most fre-
quently occurred on a single day after admission to the
study site (58%) or resolved within 2 days (22%) and
most commonly occurred on day 1 (52%; data not
shown).
COMPARISON OF PATIENTS
WITH AND WITHOUT BLEEDING
COMPLICATIONS
Clinical features of bleeders and nonbleeders are
compared in Table 2. Bleeders were more often
male than nonbleeders (40 versus 30%, respectively;
P5 0.006) but were otherwise demographically similar.
Bleeding complications occurred as frequently in
patients with acetaminophen (APAP)–induced as in
those with non-APAP-induced etiology. The time
delay of presentation for medical care (onset of ALF
symptoms to study enrollment) was similar between the
two groups (5 versus 6 days in bleeders and nonbleeders,
respectively; P5 0.10). Although bleeding episodes
prior to transfer to the study site were not recorded,
bleeders were more likely to have received plasma trans-
fusion prior to study admission (65 versus 42%, respec-
tively; P< 0.001) and more likely to have been taking
aspirin on admission (9 versus 5%, respectively;
P5 0.045) than nonbleeders. However, there was no
difference in the proportion of patients on anticoagu-
lants at the time of study admission in the two groups.
Bleeders were generally more systemically ill than
nonbleeders and had more extrahepatic organ dysfunc-
tion (Table 2). Although the prevalence of SIRS
deﬁned as two or more positive components was only
modestly higher in bleeders than nonbleeders (80 ver-
sus 74%, respectively; P5 0.127), individual compo-
nents of SIRS reﬂected a greater severity of systemic
inﬂammation in bleeders, including the two-sided
temperature (<36C or >38C, 37% versus 28%,
P5 0.014) and white blood cell criteria (<4 or
>123 109/L, 53% versus 46%, P5 0.052), pulse
(P< 0.001), and partial pressure of CO2 (P5 0.028),
with a trend toward a higher respiratory rate in
bleeders (P5 0.09). Bleeders more frequently devel-
oped high-grade (grade 3 or 4) hepatic encephalopathy
(62% versus 48% on admission and 86% versus 63%
over days 1-7) and had higher serum creatinine
(2.26 2.3 versus 1.66 2.1mg/dL), higher lactate
(5.46 8.2 versus 4.46 6.0mg/dL), lower bicarbonate
(20.06 10.0 versus 22.06 8.0mg/dL), and higher
phosphate (3.86 2.9 versus 3.16 2.3mg/dL) than
nonbleeders (P< 0.001, except for lactate and bicar-
bonate, P5 0.002). Although abnormal laboratory
parameters of extrahepatic organ dysfunction were
more severe in bleeders, bleeders and nonbleeders had
similar degrees of liver dysfunction as assessed by INR,
bilirubin, ammonia, and albumin, which were not sta-
tistically different between the two groups.
Baseline hemoglobin on admission to the study in
bleeders was lower than that in nonbleeders (10.36 2.8
versus 11.16 3.1 g/dL, respectively; P< 0.001); nadir
hemoglobin over the ﬁrst 7 days of admission was also
lower in bleeders than nonbleeders (8.46 2.1 versus
9.26 2.5 g/dL; P< 0.001). However, the mean percent
decrease in hemoglobin from admission to nadir in
bleeders and nonbleeders was similar (decrease of 15%
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FIG. 1. Blood hemoglobin concentration (grams per deciliter)
on each day after admission for ALF. (A) Hemoglobin according
to study day in early bleeders versus nonbleeders. (B) Hemoglo-
bin according to study day in patients who received RBC transfu-
sions versus those who did not. *P< 0.05, **P< 0.01,
***P< 0.001.
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and 14%, respectively), and the hemoglobin concentra-
tion was similar between the groups on each day after
day 2 (Fig. 1A).
Although both the admission and the nadir platelet
count were lower in bleeders (966 92 and 536
453 109/L) than nonbleeders (1286 108 and 776
813 109/L, respectively; both P< 0.001), the
admission and peak INR in bleeders (2.76 2.4 and
3.26 3.3) were not signiﬁcantly different from peaks
in nonbleeders (2.86 2.2 and 3.36 2.7, respectively).
In fact, bleeders had signiﬁcantly lower platelet counts
than nonbleeders on each study day (P< 0.001 for
each day; Fig. 2A), while INR was similar between the
groups on each day (Fig. 2B). There was no relation-
ship of the platelet count to the INR on admission in
bleeders or nonbleeders (r25 0.03 and 0.01, respec-
tively; data not shown).
Bleeders also received many more therapeutic inter-
ventions than nonbleeders, reﬂecting the severity of
their systemic illness (Table 2). The incidence of ICP
monitor placement (20% versus 14%) and RRT (57%
versus 34%); the administration of vasopressors (65%
versus 34%) and gastric acid suppressants (87% versus
80%); and the transfusion of plasma (64% versus 34%)
and platelets (78% versus 54%) were higher in bleeders
than nonbleeders, respectively (all P< 0.001 except for
ICP monitor placement and gastric acid suppressants,
P5 0.019 and P5 0.039, respectively). Interestingly,
transfusion of RBC in bleeders was not different from
that in nonbleeders (16% versus 17%, respectively),
again suggesting that the magnitude of the bleeding
complication was small. The administration of N-ace-
tylcysteine, which theoretically might increase bleeding
episodes by decreasing von Willebrand factor multimer
size,(13) was not associated with bleeding complications.
COMPARISON OF PATIENTS
WHO RECEIVED AND DID NOT
RECEIVE RBC TRANSFUSIONS
The clinical characteristics of patients who received
RBC transfusions differed from those of bleeders in
several regards. Many more patients received RBC
transfusions (651/1,770; 37%) than experienced bleed-
ing complications (187/1,770; 11%); of the 651 patients
who received RBC transfusions, only 120 (18%) experi-
enced bleeding complications (Table 3). However,
bleeding complications were signiﬁcantly more com-
mon in patients who received RBC transfusions than in
those who did not (18% versus 6%, respectively;
P< 0.001). Although a greater proportion of bleeders
than nonbleeders were men, a greater proportion of
those who received RBC transfusions than those who
did not were women (73% versus 67%, respectively;
P5 0.003), possibly due to the fact that women entered
the study with a lower mean hemoglobin than did men
(10.7 versus 11.9 g/dL, data not shown). In addition,
comparison of serum hemoglobin concentrations in
RBC-transfused and nontransfused patients (Fig. 1B)
suggests that the former were transfused for anemia on
admission rather than an acute drop in hemoglobin
after admission. Indeed, the mean decrease in hemoglo-
bin from admission to nadir in RBC-transfused and
nontransfused patients was similar (15% and 13%,
respectively), and the difference in hemoglobin in trans-
fused and nontransfused patients (Fig. 1B) was greater
than the difference between bleeders and nonbleeders
(Fig. 1A), both suggesting that the indication for trans-
fusion was anemia rather than bleeding.
Otherwise, patients who received RBC transfusions
resembled bleeders (Table 3): they were more acutely ill
than those who were not transfused, more frequently
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FIG. 2. INR (A) and platelet count (B) of patients on days 1-7
after admission to the study according to the occurrence of bleed-
ing complications. ***P< 0.001.
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met SIRS criteria (P5 0.002), had a higher proportion
of patients reaching high-grade (3 or 4) encephalopathy
(P< 0.001), had laboratory parameters reﬂecting more
severe systemic illness, and received more therapeutic
interventions than those who did not receive RBC
transfusions. Also similar to bleeders, receiving RBC
transfusions had no consistent relationship to the sever-
ity of liver injury by INR but was signiﬁcantly related to
the platelet count, a marker of systemic inﬂammation.
RELATIONSHIP OF BLOOD
COMPONENT TRANSFUSION TO
BLEEDING COMPLICATIONS
Although patients who experienced bleeding compli-
cations were more likely to receive transfusion of plate-
lets and/or plasma than nonbleeders (Table 2), the
majority of blood components transfused did not appear
to be in response to bleeding complications. Over the
ﬁrst 7 days of admission, 37%, 56%, and 26% of study
patients received RBC, plasma, and platelets, respec-
tively (Table 4). However, most patients who received
RBC, plasma, or platelets were nonbleeders (82%, 85%,
and 81%, respectively). In addition, 5%-6% of patients
transfused received blood components before the occur-
rence of their bleeding complication, indicating that
bleeding was not the indication for the transfusion.
Therefore, at a minimum, 87%, 91%, and 86% of
patients who received RBC, plasma, and platelets,
respectively, were transfused for an indication other
than active bleeding (for example, for nonhemorrhagic
anemia or prophylaxis before an invasive procedure).
The practice of administering blood products (RBC,
plasma, and/or platelets) during days 1-7 for any
TABLE 3. Clinical Characteristics of Patients With ALF Who Received or Did Not Receive RBC
Transfusion During Days 1-7
Clinical Feature n
No RBC Transfusions
n51,119
(Mean n, %)
RBC Transfusions
n5 651
(Mean n, %) P
Demographics
Age (years) 1,770 426 15 416 14 0.15
Gender (% female) 1,770 744 (66.5) 477 (73.3) 0.003
Race (Caucasian) 1,770 842 (75.2) 467 (71.7) 0.117
APAP etiology of ALF 1,770 523 (46.7) 275 (42.2) 0.075
Clinical features on admission
SIRS (%2) 1,364 580 (72.0) 444 (79.4) 0.002
Ammonia (mM) 1,032 98.06 90.0 101.06 97.0 0.826
Encephalopathy grade (% 3/4) 1,721 451 (41.9) 397 (61.6) <0.001
Creatinine (mg/dL) 1,766 1.36 1.9 2.16 2.3 <0.001
INR 1,770 2.96 2.2 2.86 2.2 0.129
Total bilirubin (mg/dL) 1,752 7.06 15.6 8.06 17.0 <0.001
Albumin (g/dL) 1,616 2.76 0.7 2.76 0.8 0.17
Lactate (mg/dL) 971 3.96 4.7 5.96 7.7 <0.001
Bicarbonate (mg/dL) 1,481 22.068.0 20.06 8.8 <0.001
Phosphate (mg/dL) 1,539 3.06 2.2 3.46 2.7 <0.001
Platelet count (3109/L) 1,770 133.06 104.0 108.06 102.5 <0.001
WBC (3109/L) 1,770 9.66 7.4 10.96 9.9 <0.001
Hemoglobin (g/dL) 1,764 11.562.9 9.96 2.9 <0.001
Clinical features after admission, days 1-7
INR peak 1,770 3.36 2.7 3.36 2.8 0.586
Platelet count nadir (3109/L) 1,770 94.06 81.0 50.06 48.0 <0.001
Hemoglobin nadir (g/dL) 1,770 9.86 2.5 8.26 1.6 <0.001
Encephalopathy grade 3/4 1,734 613 (56.3) 529 (82.0) <0.001
Infection 1,770 125 (11.2) 46 (7.1) 0.006
Bleeding complication 1,770 67 (6.0) 120 (18.4) <0.001
Interventions after admission, days 1-7
ICP monitor placement 1,634 99 (9.4) 138 (23.7) <0.001
RRT 1,770 271 (24.2) 370 (56.8) <0.001
Vasopressors 1,770 300 (26.8) 352 (54.1) <0.001
N-Acetylcysteine 1,770 722 (64.5) 366 (56.2) <0.001
Gastric acid suppression 1,770 892 (79.7) 537 (82.5) 0.172
Plasma transfusion 1,770 210 (18.8) 85 (13.1) 0.002
Platelet transfusion 1,770 451 (40.3) 543 (83.4) <0.001
Abbreviation: WBC, white blood cell.
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indication has decreased by 2.6%/year between 1998
and 2015. Nevertheless, the incidence of bleeding
complications has remained stable over the same time
frame (mean 10.76 3.8%/year) (Supporting Fig. S2).
Because the majority of transfusions were given as pro-
phylaxis, this observation suggests that withholding
transfusions has not increased bleeding complications
in patients with ALF.
RELATIONSHIP OF BLOOD
PRODUCT TRANSFUSION AND
BLEEDING COMPLICATIONS TO
OUTCOME OF ALF
The incidence of bleeding complications according
to 21-day outcome in spontaneous survivors, those
who underwent LT, and those who died was 7%, 5%,
and 18%, respectively. The data in Table 5 depict the
association of blood product transfusion, vitamin K,
and rFVIIa during the ﬁrst 7 days of admission to out-
come at day 21. Patients who received RBC, plasma,
or platelet transfusions were nearly twice as likely to
have died or undergone LT at day 21 than nontrans-
fused patients. Of the 944 patients who died or
underwent LT, RBC, plasma, or platelets were trans-
fused in 45%, 70%, and 32%, respectively; of 713
spontaneous survivors, transfusions were recorded in
27%, 39%, and 16%, respectively (all P< 0.001).
Receipt of any blood product was observed in approxi-
mately 70% of patients who died or underwent LT but
only approximately 30% of spontaneous survivors (data
not shown). Although relatively few patients received
rFVIIa (n5 37), most died or underwent LT (76%);
and the prevalence of receiving rFVIIa was over 3-fold
higher in this group compared to spontaneous survi-
vors (P5 0.022). Outcomes were signiﬁcantly better in
patients who received vitamin K than those who did
not, with vitamin K received by 20% of spontaneous
survivors but by only 15% of those who died or under-
went LT (P5 0.006).
As a total study population, bleeding complications
during the ﬁrst 7 days of admission were associated
with negative outcomes at day 21, with a transplant-
free survival (TFS) rate among bleeders of 28%
(median time to transplant/death 6 days; 95% conﬁ-
dence interval [CI], 4-7 days), while the TFS rate
among nonbleeders was 45% (median time to trans-
plant/death 12 days; 95% CI, 9-18 days; P< 0.001;
data not shown). However, the Kaplan-Meier curves
TABLE 4. Relationship of Blood Component Administration to Early Bleeding Complications
Blood
Component
Patients Receiving Blood Component Transfusions, n (%)
Total
Transfused
Bleeders Transfused
Nonbleeders
Transfused
Total Transfused for
Nonbleeding
Indication†
Before
Bleeding
At or After
Bleeding*
RBC 651 (37%) 34 (5.2%) 86 (13%) 531 (82%) 565 (87%)
Plasma 994 (56%) 60 (6.0%) 85 (8.6%) 849 (85%) 909 (91%)
Platelets 435 (26%) 22 (5.1%) 60 (14%) 353 (81%) 375 (86%)
*Deﬁned as patients who received blood component transfusion on the same day as, or any day after, bleeding complication.
†Includes nonbleeders who received blood component transfusions and bleeders who received transfusions before their bleeding
episodes.
TABLE 5. Relationship Between Transfusion of RBC, Plasma, or Platelets Between Days 1 and 7 to
Outcome of ALF at Day 21
Treatment
During Inpatient
(Days 1-7)
Outcome at Day 21
Spontaneous
Survivors
(n5713)
n (%)
Nonspontaneous Survivors
P*
All
(n5944)
n (%)
LT
(n5430)
n (%)
Death
(n5 599)
n (%)
Vitamin K 152 (20%) 143 (15%) 54 (13%) 92 (15%) 0.006
rVIIa 9 (1.2%) 28 (2.8%) 16 (4%) 13 (2%) 0.022
RBC transfusion 207 (27%) 444 (45%) 197 (46%) 278 (46%) <0.001
Plasma transfusion 302 (39%) 692 (70%) 312 (73%) 415 (69%) <0.001
Platelet transfusion 122 (16%) 313 (32%) 141 (33%) 192 (32%) <0.001
*P value compares probability of receiving the indicated treatment between spontaneous survivors and subjects who received LT and/
or died.
STRAVITZ ET AL. HEPATOLOGY, May 2018
1938
in Fig. 3 show that the presence of bleeding complica-
tions only affected TFS in patients with APAP-
induced ALF (TFS 34% in bleeders versus 63% in
nonbleeders; P< 0.001) but not in patients with non-
APAP ALF.
Discussion
The incidence of bleeding complications in this
large, contemporary population with ALF was approx-
imately 11%, the majority of whom had clinically
insigniﬁcant bleeding. These ﬁndings from the ALF
Study Group Registry contrast with older historical
reports, in which many patients not only bled but died
from the bleed. In an early autopsy series of patients
with ALF, Gazzard et al.(6) reported that 30% died
of a bleeding complication, 90% of whom bled from
a gastrointestinal source. Other early series reported
that the incidence of bleeding complications ranged
between 50% and 70%, with death reported from
bleeding in 30%.(5,7,14) Although the incidence and
mortality of bleeding complications have decreased for
critically ill patients in general,(15) these data support
the emerging consensus that patients with ALF are
not at major risk of signiﬁcant bleeding complications
despite their dramatically elevated INR.
The International Society of Thrombosis and Hae-
mostasis has deﬁned “major bleeding” as causing death,
occurring in a critical area or organ (including intracra-
nial), and/or the need for RBC transfusion in the set-
ting of a bleed associated with a 2 g/dL drop in
hemoglobin.(16) The preponderance of evidence in the
present series suggests that few bleeding complications
in patients with ALF would be categorized as major or
even clinically signiﬁcant. First, 87% of RBC-
transfused patients received the transfusion for an indi-
cation other than a bleeding complication, presumably
for anemia (Table 4). Second, the magnitude of
decrease in hemoglobin from study admission to nadir
within 7 days was nearly identical in patients who
experienced bleeding complications and those who did
not (decrease of 15 versus 14%, respectively). Third, in
patients who died with a reason for death recorded,
only 10 of 1,770 patients reviewed were considered to
have died as a consequence of a bleeding complication,
7 of whom died of intracranial hemorrhage, with 5 of
these likely related to ICP monitor placement. Finally,
differences in mortality between bleeders and non-
bleeders were only observed after day 7 (Fig. 3), sug-
gesting a temporal dissociation between the bleeding
episode and death. The ﬁnding that 10 patients had
intracranial bleeds in the absence of an ICP monitor,
presumably a complication of cerebral edema, has not
been reported.
Although postprocedural bleeding complications
remain a signiﬁcant concern for clinicians caring for
patients with ALF, the data suggest that they are rare.
For example, 641 patients underwent central venous
catheter placement for RRT, yet there were fewer than
ﬁve instances of bleeding at the insertion site (0.8%);
no other more serious bleeding complications were
reported. The observation appears to support a recent
series from an intensive care liver unit, in which 658
central venous cannulations in 283 patients (35%
with APAP overdose) with INR 1.5 and/or platelet
count 1503 109/L and without routine plasma or
platelet transfusion resulted in only one serious bleed-
ing complication, a hemothorax.(17) Our low incidence
of bleeding after RRT catheter insertion may have
been inﬂuenced by blood product prophylaxis, but the
above study in which plasma and platelets were only
transfused in 1.8% and 4.2% of patients, respectively,
also raises the question of whether such prophylaxis
was necessary in the ﬁrst place. The observation that
there has been a steady decline in blood component
transfusion over the 17 years of data collection by the
ALF Study Group without an increase in bleeding
                                                                 
FIG. 3. Kaplan-Meier curve of TFS according to the occurrence
of bleeding complications between days 1 and 7 in patients with
APAP-induced and non-APAP-induced ALF. Overall, the TFS
among nonbleeders was 45.2%, with a median time to trans-
plant/death occurring at 12 (95% CI, 9-18) days, and that among
bleeders was 27.6%, with a median time to transplant/death
occurring at 6 (95% CI, 4-7) days (P< 0.001). According to eti-
ology, this difference is due to a difference in patients with
APAP-induced ALF (P< 0.001); there was no signiﬁcant differ-
ence in TFS in patients with non-APAP-induced ALF accord-
ing to the occurrence of bleeding complications.
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complications (Supporting Fig. S2) also raises this
question. Intracranial bleeding after ICP monitor
placement, however, remains a signiﬁcant threat,
although it is uncommon, occurring in 10 of 237
(4.2%) of our study patients, 5 of whom (2%) probably
died of complications of the bleed. These statistics
compare favorably with fatal bleeding complication
rates of 1%, 5%, and 4% of patients with ALF who
received ICP monitors in epidural, subdural, and intra-
parenchymal locations, respectively.(18) These data
highlight the fact that placement of an ICP carries a
signiﬁcant risk of intracranial bleeding and death.
Despite their generally mild severity, bleeding com-
plications were associated with lower 21-day TFS (Fig.
3) but only for patients with APAP-induced ALF.
The occurrence of bleeding complications had no
effect on TFS in patients with non-APAP-induced
ALF. In other analyses, we have found the occurrence
of bleeding complications in patients with APAP-
induced ALF to be a marker of particularly severe
acute illness (data not shown). The 21-day outcome of
LT or death was nearly 2-fold higher in patients who
received transfusion of any blood component within
the ﬁrst 7 days of admission (Table 5). Therefore, it is
also conceivable that administering blood components
early after admission has adverse effects that are partic-
ularly signiﬁcant for patients with APAP-induced
ALF, possibly by exacerbating a preexisting hypercoag-
ulable state, resulting in microvascular thrombosis
within the liver and peripheral circulation and com-
pounding the primary liver injury(19) and poor periph-
eral tissue perfusion,(20) respectively. Other hazards of
blood product transfusion, such as volume overload,
transfusion-associated lung injury, immune dysregula-
tion, and exacerbation of intracranial hypertension, are
also possible.
The data also suggest that bleeding complications
and the development of anemia are primarily due to
severe systemic inﬂammation. In Tables 2 and 3, both
bleeders and those receiving RBC transfusions are
characterized by clinical features and laboratories sug-
gestive of more severe systemic injury than nonbleeders
and nontransfused patients, respectively. The ﬁnding
that platelet count was signiﬁcantly lower in bleeders
and RBC-transfused patients is consistent with this
hypothesis because we have recently shown in the same
patient population that the decline in platelet count
after admission is proportional to the severity of sys-
temic complications and SIRS.(11) The fact that the
INR is not different between these populations is also
consistent with our previous observations that the INR
does not vary with the severity of systemic inﬂamma-
tion. Another interpretation of these data might be
that lower platelet count, but not a higher INR, is a
more important risk factor for bleeding complications,
as has been suggested by other authors.(6)
For the vast majority of patients with ALF and UGI
bleeding, the likely source is stress-related mucosal dis-
ease, a manifestation of critical illness characterized by
intense systemic inﬂammation.(21) In a recent survey of
>1,000 intensive care unit patients, clinically signiﬁ-
cant UGI bleeding occurred in only 2.6%, but risk fac-
tors included three integral features of the ALF
syndrome: liver disease (odds ratio, 7.6), coagulopathy
(odds ratio, 5.2), and RRT (odds ratio, 6.9).(15) The
responsible lesion, subepithelial hemorrhage, is caused
by gastric mucosal ischemia proportional to the severity
of underlying illness, rather than defective hemosta-
sis.(21) Consequently, prophylaxis with acid suppres-
sion has not been universally shown to decrease its
incidence.(22) Although early studies in patients with
ALF suggested beneﬁt from histamine-2-receptor
antagonists,(23) our data suggest no apparent beneﬁt
from gastric acid inhibition. The difference between
early and contemporary series may be a recent overall
decrease in stress-related mucosal disease as a result of
improved intensive care unit care, resulting in
decreased mucosal hypoperfusion.(22)
There are multiple possible explanations for the low
incidence and mild severity of bleeding complications
in patients with ALF. Thrombin generation in ALF is
generally normal in vitro in the presence of thrombo-
modulin.(24,25) Deﬁciency of liver-derived procoagu-
lant proteins is proportional to deﬁciency of
anticoagulant proteins.(2) Von Willebrand factor and
factor VIII levels are increased dramatically due to
endothelial activation/injury from SIRS.(26,27) Procoa-
gulant microparticles are released by systemic inﬂam-
mation.(28) Finally, ﬁbrinolysis is severely impaired
such that clot lysis in many patients cannot be
detected.(24) Another obvious possibility remains
unproven: administering prophylactic blood compo-
nents to treat the high INR and low platelets is effec-
tive in decreasing bleeding complications.
We acknowledge limitations in our data and conclu-
sions. The ALF Study Group Registry was not
designed to link bleeding complications to speciﬁc pro-
cedures, blood product transfusions, and episodes of
hemodynamic instability; and post hoc analyses without
predeﬁned research questions increase the risk of bias.
Missing data led to exclusion of 24% of registry partic-
ipants with the consequences noted in Supporting
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Table S1: the apparent exclusion of less acutely ill
patients from the analysis. We emphasize, however,
that we aimed to describe a “worst-case scenario” in
order not to underemphasize the risks of bleeding in
patients with ALF; and the exclusion of these patients
should, therefore, not have contributed to an underes-
timate of the risk. Although an earlier version of the
Registry Operations Protocol Manual required quantita-
tion of administered blood products, a later version has
not. The clinical indication for transfusion of a speciﬁc
blood product was also not captured. Therefore, some
of our conclusions were admittedly reached on circum-
stantial evidence.
In conclusion, bleeding complications in patients
with ALF are primarily clinically insigniﬁcant. Sponta-
neous bleeding complications are comprised over-
whelmingly of self-limited UGI bleeding, which
appears to have decreased in incidence and severity
over the last 40 years. Postprocedural complications
remain rare, and those linked to the death of patients
with ALF were universally complications of ICP mon-
itor placement. Transfusion of blood components is
associated with increased 21-day poor outcome (LT
and/or death). Future study must answer an important
question raised by this report: does prohemostatic
blood component transfusion decrease bleeding com-
plications or adversely affect patients with ALF?
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